31 Result(s)

Article

Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials

Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range from 2 to 10%. The aim of this analysis is to report ...

O. Al-Sawaf, S. Robrecht, J. Bahlo, A. M. Fink, P. Cramer, J. v Tresckow… in Leukemia (2021)

Article

Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia

M. Fürstenau, J. Bahlo, A. M. Fink, E. Lange, P. Dreger, M. Dreyling, G. Hess… in Leukemia (2020)

Article

Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials

E Hoster, C H Geisler, J Doorduijn, B van der Holt, J Walewski, J Bloehdorn… in Leukemia (2016)

Article

Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial

S Ferrero, A Pastore, C W Scholz, R Forstpointner, A Pezzutto, L Bergmann… in Leukemia (2016)

Article

Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus

Approximately 15% of follicular lymphomas (FLs) lack breaks in the BCL2 locus. The aim of this study was to better define molecular and clinical features of BCL2-breakpoint/t(14;18)-negative FLs. We studied the p...

E Leich, E Hoster, M Wartenberg, M Unterhalt, R Siebert, K Koch, W Klapper… in Leukemia (2016)

Article

Aktuelle Therapiestrategien beim follikulären Lymphom

In den letzten Jahren haben sich in der Behandlung follikulärer Lymphome wesentliche Fortschritte ergeben, die zu einer substanziellen Verbesserung der Prognose betroffener Patienten geführt haben. Bei Patient...

Prof. Dr. W. Hiddemann, E. Hoster, C. Schmidt, M. Dreyling, M. Unterhalt in Der Internist (2016)

Chapter

Therapie der indolenten Non-Hodgkin-Lymphome

Ziel. Dieser Artikel gibt einen Überblick über aktuelle Therapiestrategien bei indolenten Lymphomen.

T. Seiler, K. Herfarth, W. Klapper, M. Dreyling in Weiterbildung Onkologie (2016)

Article

Indolente Lymphome

Indolente Lymphome sind gekennzeichnet durch langsames Wachstum und lange therapiefreie Zeiträume. Der häufigste Vertreter ist das follikuläre Lymphom.

PD Dr. A. Viardot, K. Herfarth, M. Dreyling in Der Onkologe (2015)

Article

Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma

In this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with r/r follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1–3 prior...

G Hess, U Keller, C W Scholz, M Witzens-Harig, J Atta, C Buske, S Kirschey… in Leukemia (2015)

Article

Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma

Prognosis is poor for patients with biologically aggressive Non-Hodgkin lymphoma (NHL), refractory to chemotherapy or relapsed after autologous transplantation, especially when no disease control before alloge...

A-K Zoellner, S Fritsch, D Prevalsek, N Engel, M Hubmann… in Bone Marrow Transplantation (2015)

Article

The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma

The role of both autologous (autoSCT) and allogeneic stem cell transplantation (alloSCT) in the management of mantle cell lymphoma (MCL) remains to be clarified. We conducted a consensus project using the RAND...

S Robinson, P Dreger, D Caballero, P Corradini, C Geisler, M Ghielmini… in Leukemia (2015)

Article

How to manage mantle cell lymphoma

Mantle cell lymphoma (MCL) is no longer a hopeless disease. Considered to carry a uniformly dismal prognosis so far, during the last years it has been rediscovered as a heterogeneous clinical and biological en...

M Dreyling, S Ferrero, O Hermine in Leukemia (2014)

Article

Therapie der indolenten Non-Hodgkin-Lymphome

Dieser Artikel gibt einen Überblick über aktuelle Therapiestrategien bei indolenten Lymphomen.

Dr. T. Seiler, K. Herfarth, W. Klapper, M. Dreyling in Der Onkologe (2014)

Article

Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting

In most patients, mantle cell lymphoma (MCL) shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3–5 years. In the current study generation of the European MCL N...

M. Witzens-Harig, G. Hess, J. Atta, M. Zaiss, G. Lenz, C. Scholz… in Annals of Hematology (2012)

Article

Proteasome inhibition leads to dephosphorylation and downregulation of protein expression of members of the Akt/mTOR pathway in MCL

G Hutter, Y Zimmermann, M Rieken, E Hartmann, A Rosenwald, W Hiddemann… in Leukemia (2012)

Article

Allelic genoty** reveals a hierarchy of genomic alterations in mantle cell lymphoma associated to cell proliferation

Mantle cell lymphoma (MCL) is a distinct subentity of non-Hodgkin lymphoma, characterized by the chromosomal translocation t(11;14)(q13;q32) leading to an overexpression of cyclin D1 in virtually all cases. Ho...

G. Hutter, M. Scheubner, G. Ott, Y. Zimmermann, K. Hübler, S. Roth… in Annals of Hematology (2009)

Article

The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)

Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab to standard chemotherapy improves trea...

C Buske, E Hoster, M Dreyling, H Eimermacher, H Wandt, B Metzner, R Fuchs… in Leukemia (2009)

Article

Detailed map** of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma

Deletions in the short arm of chromosome 17 (17p) involving the tumor suppressor TP53 occur in up to 20% of diffuse large B-cell lymphomas (DLBCLs). Although inactivation of both alleles of a tumor suppressor gen...

H Stöcklein, J Smardova, J Macak, T Katzenberger, S Höller, S Wessendorf… in Oncogene (2008)